United States Biotechnology & Medical Research

Dyne Therapeutics Inc (DYN)

Track

Track

Dyne Therapeutics experienced significant insider trading activity recently, with 63 transactions totaling over $210 million in sales. Major shareholders and executives, including the CEO, executed planned divestments. This selling follows a July earnings report that missed expectations. Current market valuation sits well below the annual peak, reflecting ongoing volatility within the healthcare sector.
Ticker: DYN Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Dyne Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
2.1
Cox John Officer Officer
Transaction date
Proposed sale
Price
185.39
Quantity 69,179
Value US$1,408,900
Kerr Douglas Officer Officer
Transaction date
Proposed sale
Price
388.98
Quantity 24,605
Value US$2,746,953
0.9
Friedl-Naderer Johanna Chief Commercial Officer Officer
Transaction date
Planned sale
Price
311.73
Quantity 33,708 +39.0%
Value US$3,086,719
Kerr Douglas Chief Medical Officer Officer
Transaction date
Planned sale
Price
18.88
Quantity 1,290 -0.8%
Value US$24,355
2.1
Cox John CEO & President Executive Director
Transaction date
Planned sale
Price
18.88
Quantity 5,658 -1.6%
Value US$106,823
0.9
Friedl-Naderer Johanna Chief Commercial Officer Officer
Transaction date
Planned sale
Price
24.35
Quantity 900 -0.6%
Value US$21,915
Kerr Douglas Chief Medical Officer Officer
Transaction date
Planned sale
Price
24.35
Quantity 3,745 -2.2%
Value US$91,191
Kerr Douglas Officer Officer
Transaction date
Proposed sale
Price
24.35
Quantity 5,000
Value US$121,745
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
25.00
Quantity 322,465 -42.9%
Value US$8,061,625
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
25.00
Quantity 478,377 -45.7%
Value US$11,959,425
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
25.00
Quantity 1,359,674 -35.8%
Value US$33,991,850
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
26.20
Quantity 63,643 -7.8%
Value US$1,667,447
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
26.20
Quantity 94,415 -8.3%
Value US$2,473,673
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
26.20
Quantity 268,354 -6.6%
Value US$7,030,875
0.9
Friedl-Naderer Johanna Chief Commercial Officer Officer
Transaction date
Planned sale
Price
26.28
Quantity 226 -0.1%
Value US$5,939
Kerr Douglas Chief Medical Officer Officer
Transaction date
Planned sale
Price
26.28
Quantity 1,556 -0.9%
Value US$40,892
3.6
Lucera Erick Chief Financial Officer Officer
Transaction date
Planned sale
Price
26.28
Quantity 1,797 -1.5%
Value US$47,225
2.1
Cox John CEO & President Executive Director
Transaction date
Planned sale
Price
26.28
Quantity 4,986 -1.4%
Value US$131,032
2.1
Cox John Officer Officer
Transaction date
Proposed sale
Price
26.28
Quantity 4,986
Value US$131,034
Kerr Douglas Officer Officer
Transaction date
Proposed sale
Price
26.28
Quantity 2,443
Value US$64,203
3.6
Lucera Erick Officer Officer
Transaction date
Proposed sale
Price
26.28
Quantity 1,797
Value US$47,226
3.9
Kersten Dirk Non-Executive Director
Transaction date
Planned sale
Price
26.04
Quantity 5,388 -0.1%
Value US$140,319
3.9
Kersten Dirk Non-Executive Director
Transaction date
Planned sale
Price
25.50
Quantity 256,072 -6.7%
Value US$6,530,451
ForDyne B.V. Affiliate
Transaction date
Proposed sale
Price
25.51
Quantity 261,460
Value US$6,670,760
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Sale
Price
23.61
Quantity 5,000 -62.8%
Value US$118,050
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.62
Quantity 11,665 -1.4%
Value US$275,527
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.17
Quantity 49,193 -5.6%
Value US$1,139,802
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.62
Quantity 14,844 -1.3%
Value US$350,615
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.17
Quantity 62,543 -5.1%
Value US$1,449,121
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.62
Quantity 29,587 -0.7%
Value US$698,845
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
23.17
Quantity 124,379 -2.9%
Value US$2,881,861
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
22.79
Quantity 100,019 -10.2%
Value US$2,279,433
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
22.79
Quantity 127,182 -9.5%
Value US$2,898,478
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
22.79
Quantity 253,039 -5.7%
Value US$5,766,759
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.14
Quantity 40,702 -4.0%
Value US$860,440
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.14
Quantity 51,756 -3.7%
Value US$1,094,122
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.14
Quantity 102,969 -2.2%
Value US$2,176,765
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.28
Quantity 64,411 -6.0%
Value US$1,370,666
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.28
Quantity 81,903 -5.5%
Value US$1,742,896
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.28
Quantity 162,954 -3.4%
Value US$3,467,661
3.6
Lucera Erick Chief Financial Officer Officer
Transaction date
Sale
Price
20.37
Quantity 2,362 -1.9%
Value US$48,114
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.10
Quantity 5,019 -0.5%
Value US$105,901
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.10
Quantity 6,382 -0.4%
Value US$134,660
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.10
Quantity 12,699 -0.3%
Value US$267,949
3.6
Lucera Erick Officer Officer
Transaction date
Proposed sale
Price
20.37
Quantity 2,362
Value US$48,103
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.02
Quantity 19,973 -1.8%
Value US$419,832
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.02
Quantity 25,397 -1.7%
Value US$533,845
3.5
Rhodes Jason P Non-Executive Director
Transaction date
Planned sale
Price
21.02
Quantity 50,530 -1.1%
Value US$1,062,141
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-09-08 2026-09-08 PrS Proposed sale
2.1
Cox John

Officer

Officer
69,179
185.39
US$1,408,900 		69,179 185.39 US$1,408,900
2026-09-08 2026-09-08 PrS Proposed sale
Kerr Douglas

Officer

Officer
24,605
388.98
US$2,746,953 		24,605 388.98 US$2,746,953
2026-09-08 2026-09-08 PlS Planned sale
0.9
Friedl-Naderer Johanna

Chief Commercial Officer

Officer
33,708 +39.0%
311.73
US$3,086,719 		33,708 +39.0% 311.73 US$3,086,719
2026-09-08 2026-09-08 PlS Planned sale
Kerr Douglas

Chief Medical Officer

Officer
1,290 -0.8%
18.88
US$24,355 		1,290 -0.8% 18.88 US$24,355
2026-09-08 2026-09-08 PlS Planned sale
2.1
Cox John

CEO & President

Executive Director
5,658 -1.6%
18.88
US$106,823 		5,658 -1.6% 18.88 US$106,823
2026-09-08 2026-09-04 PlS Planned sale
0.9
Friedl-Naderer Johanna

Chief Commercial Officer

Officer
900 -0.6%
24.35
US$21,915 		900 -0.6% 24.35 US$21,915
2026-09-08 2026-09-04 PlS Planned sale
Kerr Douglas

Chief Medical Officer

Officer
3,745 -2.2%
24.35
US$91,191 		3,745 -2.2% 24.35 US$91,191
2026-09-04 2026-09-04 PrS Proposed sale
Kerr Douglas

Officer

Officer
5,000
24.35
US$121,745 		5,000 24.35 US$121,745
2026-08-17 2026-08-14 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
322,465 -42.9%
25.00
US$8,061,625 		322,465 -42.9% 25.00 US$8,061,625
2026-08-17 2026-08-14 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
478,377 -45.7%
25.00
US$11,959,425 		478,377 -45.7% 25.00 US$11,959,425
2026-08-17 2026-08-14 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
1,359,674 -35.8%
25.00
US$33,991,850 		1,359,674 -35.8% 25.00 US$33,991,850
2026-08-14 2026-08-14 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
322,465
25.96
US$8,371,191 		322,465 25.96 US$8,371,191
2026-08-14 2026-08-14 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
478,377
25.96
US$12,418,667 		478,377 25.96 US$12,418,667
2026-08-14 2026-08-14 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
1,359,674
25.96
US$35,297,137 		1,359,674 25.96 US$35,297,137
2026-08-17 2026-08-13 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
63,643 -7.8%
26.20
US$1,667,447 		63,643 -7.8% 26.20 US$1,667,447
2026-08-17 2026-08-13 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
94,415 -8.3%
26.20
US$2,473,673 		94,415 -8.3% 26.20 US$2,473,673
2026-08-17 2026-08-13 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
268,354 -6.6%
26.20
US$7,030,875 		268,354 -6.6% 26.20 US$7,030,875
2026-08-17 2026-08-13 PlS Planned sale
0.9
Friedl-Naderer Johanna

Chief Commercial Officer

Officer
226 -0.1%
26.28
US$5,939 		226 -0.1% 26.28 US$5,939
2026-08-17 2026-08-13 PlS Planned sale
Kerr Douglas

Chief Medical Officer

Officer
1,556 -0.9%
26.28
US$40,892 		1,556 -0.9% 26.28 US$40,892
2026-08-17 2026-08-13 PlS Planned sale
3.6
Lucera Erick

Chief Financial Officer

Officer
1,797 -1.5%
26.28
US$47,225 		1,797 -1.5% 26.28 US$47,225
2026-08-17 2026-08-13 PlS Planned sale
2.1
Cox John

CEO & President

Executive Director
4,986 -1.4%
26.28
US$131,032 		4,986 -1.4% 26.28 US$131,032
2026-08-13 2026-08-13 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
268,354
26.17
US$7,022,824 		268,354 26.17 US$7,022,824
2026-08-13 2026-08-13 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
94,415
26.17
US$2,470,841 		94,415 26.17 US$2,470,841
2026-08-13 2026-08-13 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
63,643
26.17
US$1,665,537 		63,643 26.17 US$1,665,537
2026-08-13 2026-08-13 PrS Proposed sale
2.1
Cox John

Officer

Officer
4,986
26.28
US$131,034 		4,986 26.28 US$131,034
2026-08-13 2026-08-13 PrS Proposed sale
Kerr Douglas

Officer

Officer
2,443
26.28
US$64,203 		2,443 26.28 US$64,203
2026-08-13 2026-08-13 PrS Proposed sale
3.6
Lucera Erick

Officer

Officer
1,797
26.28
US$47,226 		1,797 26.28 US$47,226
2026-07-29 2026-07-27 PlS Planned sale
3.9
Kersten Dirk
Non-Executive Director
5,388 -0.1%
26.04
US$140,319 		5,388 -0.1% 26.04 US$140,319
2026-07-29 2026-07-27 PlS Planned sale
3.9
Kersten Dirk
Non-Executive Director
256,072 -6.7%
25.50
US$6,530,451 		256,072 -6.7% 25.50 US$6,530,451
2026-07-27 2026-07-27 PrS Proposed sale
ForDyne B.V.

Affiliate
261,460
25.51
US$6,670,760 		261,460 25.51 US$6,670,760
2026-07-08 2026-07-07 S Sale
3.5
Rhodes Jason P
Non-Executive Director
5,000 -62.8%
23.61
US$118,050 		5,000 -62.8% 23.61 US$118,050
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
11,665 -1.4%
23.62
US$275,527 		11,665 -1.4% 23.62 US$275,527
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
49,193 -5.6%
23.17
US$1,139,802 		49,193 -5.6% 23.17 US$1,139,802
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
14,844 -1.3%
23.62
US$350,615 		14,844 -1.3% 23.62 US$350,615
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
62,543 -5.1%
23.17
US$1,449,121 		62,543 -5.1% 23.17 US$1,449,121
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
29,587 -0.7%
23.62
US$698,845 		29,587 -0.7% 23.62 US$698,845
2026-07-08 2026-07-07 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
124,379 -2.9%
23.17
US$2,881,861 		124,379 -2.9% 23.17 US$2,881,861
2026-07-07 2026-07-07 PrS Proposed sale
ATLAS VENTURE ASSOCIATES XI, L.P.

Shareholder
5,000
22.84
US$114,200 		5,000 22.84 US$114,200
2026-07-07 2026-07-07 PrS Proposed sale
ATLAS VENTURE ASSOCIATES XI, L.P.

Shareholder
5,000
22.84
US$114,200 		5,000 22.84 US$114,200
2026-07-07 2026-07-07 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
153,966
22.84
US$3,516,583 		153,966 22.84 US$3,516,583
2026-07-07 2026-07-07 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
153,966
22.84
US$3,516,583 		153,966 22.84 US$3,516,583
2026-07-07 2026-07-07 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
77,387
22.84
US$1,767,519 		77,387 22.84 US$1,767,519
2026-07-07 2026-07-07 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
77,387
22.84
US$1,767,519 		77,387 22.84 US$1,767,519
2026-07-07 2026-07-07 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
60,858
22.84
US$1,389,997 		60,858 22.84 US$1,389,997
2026-07-07 2026-07-07 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
60,858
22.84
US$1,389,997 		60,858 22.84 US$1,389,997
2026-07-08 2026-07-06 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
100,019 -10.2%
22.79
US$2,279,433 		100,019 -10.2% 22.79 US$2,279,433
2026-07-08 2026-07-06 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
127,182 -9.5%
22.79
US$2,898,478 		127,182 -9.5% 22.79 US$2,898,478
2026-07-08 2026-07-06 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
253,039 -5.7%
22.79
US$5,766,759 		253,039 -5.7% 22.79 US$5,766,759
2026-07-06 2026-07-06 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
253,039
23.07
US$5,837,610 		253,039 23.07 US$5,837,610
2026-07-06 2026-07-06 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
100,019
23.07
US$2,307,438 		100,019 23.07 US$2,307,438
2026-07-06 2026-07-06 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
127,182
23.07
US$2,934,089 		127,182 23.07 US$2,934,089
2026-06-30 2026-06-29 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
40,702 -4.0%
21.14
US$860,440 		40,702 -4.0% 21.14 US$860,440
2026-06-30 2026-06-29 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
51,756 -3.7%
21.14
US$1,094,122 		51,756 -3.7% 21.14 US$1,094,122
2026-06-30 2026-06-29 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
102,969 -2.2%
21.14
US$2,176,765 		102,969 -2.2% 21.14 US$2,176,765
2026-06-29 2026-06-29 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
51,756
20.94
US$1,083,771 		51,756 20.94 US$1,083,771
2026-06-29 2026-06-29 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
102,969
20.94
US$2,156,171 		102,969 20.94 US$2,156,171
2026-06-29 2026-06-29 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
40,702
20.94
US$852,300 		40,702 20.94 US$852,300
2026-06-30 2026-06-26 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
64,411 -6.0%
21.28
US$1,370,666 		64,411 -6.0% 21.28 US$1,370,666
2026-06-30 2026-06-26 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
81,903 -5.5%
21.28
US$1,742,896 		81,903 -5.5% 21.28 US$1,742,896
2026-06-30 2026-06-26 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
162,954 -3.4%
21.28
US$3,467,661 		162,954 -3.4% 21.28 US$3,467,661
2026-06-26 2026-06-26 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
81,903
20.61
US$1,688,021 		81,903 20.61 US$1,688,021
2026-06-26 2026-06-26 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
162,954
20.61
US$3,358,482 		162,954 20.61 US$3,358,482
2026-06-26 2026-06-26 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
64,411
20.61
US$1,327,511 		64,411 20.61 US$1,327,511
2026-06-26 2026-06-25 S Sale
3.6
Lucera Erick

Chief Financial Officer

Officer
2,362 -1.9%
20.37
US$48,114 		2,362 -1.9% 20.37 US$48,114
2026-06-26 2026-06-25 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
5,019 -0.5%
21.10
US$105,901 		5,019 -0.5% 21.10 US$105,901
2026-06-26 2026-06-25 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
6,382 -0.4%
21.10
US$134,660 		6,382 -0.4% 21.10 US$134,660
2026-06-26 2026-06-25 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
12,699 -0.3%
21.10
US$267,949 		12,699 -0.3% 21.10 US$267,949
2026-06-25 2026-06-25 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
6,382
20.33
US$129,746 		6,382 20.33 US$129,746
2026-06-25 2026-06-25 PrS Proposed sale
Atlas Venture Opportunity Fund I, LP

Shareholder
5,019
20.33
US$102,036 		5,019 20.33 US$102,036
2026-06-25 2026-06-25 PrS Proposed sale
2.0
Atlas Venture Fund XI, LP

Shareholder
12,699
20.33
US$258,171 		12,699 20.33 US$258,171
2026-06-25 2026-06-25 PrS Proposed sale
3.6
Lucera Erick

Officer

Officer
2,362
20.37
US$48,103 		2,362 20.37 US$48,103
2026-06-26 2026-06-24 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
19,973 -1.8%
21.02
US$419,832 		19,973 -1.8% 21.02 US$419,832
2026-06-26 2026-06-24 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
25,397 -1.7%
21.02
US$533,845 		25,397 -1.7% 21.02 US$533,845
2026-06-26 2026-06-24 PlS Planned sale
3.5
Rhodes Jason P
Non-Executive Director
50,530 -1.1%
21.02
US$1,062,141 		50,530 -1.1% 21.02 US$1,062,141
2026-06-24 2026-06-24 PrS Proposed sale
3.4
Atlas Venture Opportunity Fund II, LP

Shareholder
25,397
20.26
US$514,543 		25,397 20.26 US$514,543
Explore more

More insider trading research around Dyne Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America